Module 3
Post-Traumatic Stress
Did You Know?
Pooled phase-2 data showed that MDMA-assisted therapy for PTSD had an extremely high Cohen’s D effect size of 0.9, compared to that of two leading FDA-approved drug treatments for PTSD, roughly triple the effect size of the SSRI sertraline (0.31) and double that of the SSRI paroxetine (0.45) (Feduccia et al., 2019).
Did You Know?
Pooled phase-2 data showed that MDMA-assisted therapy for PTSD had an extremely high Cohen’s D effect size of 0.9, compared to that of two leading FDA-approved drug treatments for PTSD, roughly triple the effect size of the SSRI sertraline (0.31) and double that of the SSRI paroxetine (0.45) (Feduccia et al., 2019).
Module Description
Building on what we learned last module about depression and anxiety, our focus this module will be on post-traumatic stress. We will look at how post-traumatic stress disorder is diagnosed in the DSM, including a commonly used screening and monitoring tool. We will also discuss common comorbidities, of which anxiety and depression are included, as well as other transdiagnostic considerations.
Learning Outcomes
Upon successful completion of the module, you will be able to:
- Identify which psychedelic medicines have been used for psychedelic-assisted therapy in the treatment of post-traumatic stress.
- Describe key evidence-based literature supporting the use of psychedelic-assisted therapy in the treatment of post-traumatic stress.
- Compare the DSM criteria and use a transdiagnostic framework understanding for post-traumatic stress.
- Justify the rationale for using a transdiagnostic approach to the treatment of post-traumatic stress.
- Describe the role that shame plays in post-traumatic stress and therapeutic approaches to working with shame.
References
Feduccia, A. A., Jerome, L., Yazar-Klosinski, B., Emerson, A., Mithoefer, M. C., & Doblin, R. (2019). Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Frontiers in psychiatry, 10, 650.